Therapeutic resistance in lung cancer

Bibliography

• KRUG LM: Vaccine therapy for small cell lung cancer. Semin. Oncol. (2004) 31:112-116.
   PubMed Web of Science ®Google Scholar
• ARRIAGADA R, LE PECHOUX C, PIGNON JP: Resected non-small cell lung cancer: need for adjuvant lymph node treatment? From hope to reality. Lung Cancer (2003) 42:S57-S64.
   PubMed Web of Science ®Google Scholar
• HOFFMAN PC, MAUER AM, VOKES EE: Lung cancer. Lancet (2000) 355(9202):479-485.
   PubMed Web of Science ®Google Scholar
• CAYUELA A, RODRIGUEZ-DOMINGUEZ S, LOPEZ-CAMPOS JL, OTERO CANDELERA R, RODRIGUEZ MATUTES C: Joinpoint regression analysis of lung cancer mortality, Andalusia 1975 – 2000. Ann.Oncol. (2004) 15(5):793-796.
   PubMed Web of Science ®Google Scholar
• HENSCHKE CI, SHAHAM D, YANKELEVITZ DF et al.: CT screening for lung cancer: significance of diagnoses in its baseline cycle. Clin. Imaging (2006) 30(1):11-15.
   PubMed Web of Science ®Google Scholar
• MULSHINE JL: New developments in lung cancer screening. J. Clin. Oncol. (2005) 23(14):3198-3202.
   PubMed Web of Science ®Google Scholar
• WOODS RL, FOX RM, TATTERSALL MH: Treatment of small cell bronchogenic carcinoma with VM-26. Cancer Treat. Rep. (1979) 63(11-12):2011-2013.
   PubMedGoogle Scholar
• TRANUM BL, HAUT A, RIVKIN S et al.: A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: a Southwest Oncology Group study. Cancer (1975) 35(4):1148-1153.
   PubMed Web of Science ®Google Scholar
• KRAUSS S, LOWENBRAUN S, BARTOLUCCI A, BUCHANAN R, BIRCH R: Alternating non-cross-resistant drug combinations in the treatment of metastatic small-cell carcinoma of the lung. Cancer Clin. Trials (1981) 4(2):147-153.
   PubMedGoogle Scholar
• HARPER PG, DALLY MB, GEDDES DM, SPIRO SG, SMYTH JF, SOUHAMI RL: Epipodophyllotoxin (VP16-213) in small cell carcinoma of the Bronchus resistant to initial combination chemotherapy. Cancer Chemother. Pharmacol. (1982) 7(2-3):179-180.
   PubMed Web of Science ®Google Scholar
• FUKS JZ, AISNER J, CARNEY DN et al.: A phase II trail of vindesine in patients with refractory small-cell carcinoma of the lung. Am. J. Clin. Oncol. (1982) 5(1):49-52.
   PubMed Web of Science ®Google Scholar
• ARONEY RS, BELL DR, CHAN WK, DALLEY DN, LEVI JA: Alternating non-cross-resistant combination chemotherapy for small cell anaplastic carcinoma of the lung. Cancer (1982) 49(12):2449-2454.
   PubMed Web of Science ®Google Scholar
• LEMAISTRE CF, KNIGHT WA 3rd: High dose chemotherapy with autologous marrow rescue in the treatment of resistant solid tumors. Invest. New Drugs (1983) 1(4):321-329.
   PubMedGoogle Scholar
• CURT GA, CARNEY DN, COWAN KH et al.: Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N. Engl. J. Med. (1983) 308(4):199-202.
   PubMed Web of Science ®Google Scholar
• SHOEMAKER RH, CURT GA, CARNEY DN: Evidence for multidrug-resistant cells in human tumor cell populations. Cancer Treat. Rep. (1983) 67(10):883-888.
   PubMedGoogle Scholar
• NATALE RB, WITTES RE: Alternating combination chemotherapy regimens in small-cell lung cancer. Semin. Oncol. (1985) 12(1 Suppl 2):7-13.
   PubMedGoogle Scholar
• FELD R, EVANS WK, COY P et al.: Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J. Clin. Oncol. (1987) 5(9):1401-1409.
   PubMed Web of Science ®Google Scholar
• EVANS WK, FELD R, MURRAY N et al.: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann. Intern. Med. (1987) 107(4):451-458.
   PubMed Web of Science ®Google Scholar
• WOLF M, HAVEMANN K, HOLLE R et al.: Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. J. Clin. Oncol. (1987) 5(12):1880-1889.
   PubMed Web of Science ®Google Scholar
• TANNOCK IF: New perspectives in combined radiotherapy and chemotherapy treatment. Lung Cancer (1994) 10(Suppl. 1):S29-S51.
   PubMed Web of Science ®Google Scholar
• CARNEY DN: The biology of lung cancer. Curr. Opin. Pulm. Med. (1995) 1(4):271-277.
   PubMedGoogle Scholar
• CARNEY DN, GAZDAR AF, NAU M, MINNA JD: Biological heterogeneity of small cell lung cancer. Semin. Oncol. (1985) 12(3):289-303.
   PubMed Web of Science ®Google Scholar
• ENGELHOLM SA, SPANG-THOMSEN M, VINDELOV LL, BRUNNER N: Effect of melphalan on growth curves and cell cycle distribution of four human small cell carcinomas of the lung grown in nude mice. Exp. Cell Biol. (1986) 54(3):138-148.
   PubMedGoogle Scholar
• BRANDES A, SOESAN M, FIORENTINO MV: Medical treatment of high grade malignant gliomas in adults: an overview. Anticancer Res. (1991) 11(2):719-727.
   PubMed Web of Science ®Google Scholar
• SINGHAL SS, SINGHAL J, SHARMA R et al.: Role of RLIP76 in lung cancer doxorubicin resistance: I. The ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistance in lung cancer cells. Int. J. Oncol. (2003) 22(2):365-375.
   PubMed Web of Science ®Google Scholar
• AWASTHI S, SINGHAL SS, SINGHAL J, CHENG J, ZIMNIAK P, AWASTHI YC: Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76. Int. J. Oncol. (2003) 22(4):713-720.
   PubMed Web of Science ®Google Scholar
• AWASTHI S, SINGHAL SS, SINGHAL J, YANG Y, ZIMNIAK P, AWASTHI YC: Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity. Int. J. Oncol. (2003) 22(4):721-732.
   PubMed Web of Science ®Google Scholar
• BERMAN R, GUSTERSON B, STEEL GG: Resistance to alkylating agents and tumour differentiation in xenografts of small cell lung cancer. Br. J. Cancer (1985) 51(5):653-658.
   PubMed Web of Science ®Google Scholar
• CURT GA, JOLIVET J, CARNEY DN et al.: Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. J. Clin. Invest. (1985) 76(4):1323-1329.
   PubMed Web of Science ®Google Scholar
• AWASTHI S, SHARMA R, SINGHAL SS, ZIMNIAK P, AWASTHI YC: RLIP76, a novel transporter catalyzing ATP-dependent efflux of xenobiotics. Drug Metab. Dispos. (2002) 30(12):1300-1310.
   PubMed Web of Science ®Google Scholar
• AWASTHI S, SINGHAL SS, SHARMA R, ZIMNIAK P, AWASTHI YC: Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): a novel link between G-protein and tyrosine kinase signaling and drug resistance. Int. J. Cancer (2003) 106(5):635-646.
   PubMed Web of Science ®Google Scholar
• STUCKLER D, SINGHAL J, SINGHAL SS, YADAV S, AWASTHI YC, AWASTHI S: RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. Cancer Res. (2005) 65(3):991-998.
   PubMed Web of Science ®Google Scholar
• AWASTHI S, SINGHAL SS, YADAV S et al.: RLIP76 is a major determinant of radiation sensitivity. Cancer Res. (2005) 65(14):6022-6028.
   PubMed Web of Science ®Google Scholar
• JAKOBY WB: The glutathione S-transferases: a group of multifunctional detoxification proteins. Adv. Enzymol. Relat. Areas Mol. Biol. (1978) 46:383-414.
   PubMedGoogle Scholar
• HAYES JD, PULFORD DJ: The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. (1995) 30(6):445-600.
   PubMed Web of Science ®Google Scholar
• FANG YZ, YANG S, WU G: Free radicals, antioxidants, and nutrition. Nutrition (2002) 18(10):872-879.
   PubMed Web of Science ®Google Scholar
• ETHIER SP: Signal transduction pathways: the molecular basis for targeted therapies. Semin. Radiat. Oncol. (2002) 12(3 Suppl. 2):3-10.
   PubMed Web of Science ®Google Scholar
• KING TC, ESTALILLA OC, SAFRAN H: Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. Semin. Radiat. Oncol. (1999) 9(2 Suppl. 1):4-11.
   PubMedGoogle Scholar
• CAMPLING BG, EL-DEIRY WS: Clinical implications of p53 mutations in lung cancer. Methods Mol. Med. (2003) 75:53-77.
   PubMedGoogle Scholar
• FUJIWARA T, GRIMM EA, MUKHOPADHYAY T, ZHANG WW, OWEN-SCHAUB LB, ROTH JA: Induction of chemo-sensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. (1994) 54(9):2287-2291.
   PubMed Web of Science ®Google Scholar
• GOLDSMITH ME, GUDAS JM, SCHNEIDER E, COWAN KH: Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J. Biol. Chem. (1995) 270(4):1894-1898.
   PubMed Web of Science ®Google Scholar
• ZHAO H, SPITZ MR, TOMLINSON GE, ZHANG H, MINNA JD, WU X: Gamma-radiation-induced G2 delay, apoptosis, and p53 response as potential susceptibility markers for lung cancer. Cancer Res. (2001) 61(21):7819-7824.
   PubMed Web of Science ®Google Scholar
• VIKTORSSON K, DE PETRIS L, LEWENSOHN R: The role of p53 in treatment responses of lung cancer. Biochem. Biophys. Res. Commun. (2005) 331(3):868-880.
   PubMed Web of Science ®Google Scholar
• WANG Y, BLANDINO G, GIVOL D: Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene (1999) 18(16):2643-2649.
   PubMed Web of Science ®Google Scholar
• NAKANISHI Y, KAWASAKI M, BAI F et al.: Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer. Oncology (1999) 57(4):318-323.
   PubMed Web of Science ®Google Scholar
• SLEBOS RJ, RODENHUIS S: The molecular genetics of human lung cancer. Eur. Respir. J. (1989) 2(5):461-469.
   PubMed Web of Science ®Google Scholar
• KOO HM, MONKS A, MIKHEEV A et al.: Enhanced sensitivity to 1-β-d-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res. (1996) 56(22):5211-5216.
   PubMed Web of Science ®Google Scholar
• VOLM M, STAMMLER G: Retinoblastoma (Rb) protein expression and resistance in squamous cell lung carcinomas. Anticancer Res. (1996) 16(2):891-894.
   PubMed Web of Science ®Google Scholar
• O'LOUGHLIN C, HEENAN M, COYLE S, CLYNES M: Altered cell cycle response of drug-resistant lung carcinoma cells to doxorubicin. Eur. J. Cancer (2000) 36(9):1149-1160.
   PubMed Web of Science ®Google Scholar
• MINEMOTO Y, UCHIDA S, OHTSUBO M et al.: Loss of p53 induces M-phase retardation following G2 DNA damage checkpoint abrogation. Arch. Biochem. Biophys. (2003) 412(1):13-19.
   PubMed Web of Science ®Google Scholar
• PAUL EC, QUARONI A: Identification of a 102 kDa protein (cytocentrin) immunologically related to keratin 19, which is a cytoplasmically derived component of the mitotic spindle pole. J. Cell. Sci. (1993) 106(Pt 3):967-981.
   PubMed Web of Science ®Google Scholar
• MORINAKA K, KOYAMA S, NAKASHIMA S et al.: Epsin binds to the EH domain of POB1 and regulates receptor-mediated endocytosis. Oncogene (1999) 18(43):5915-5922.
   PubMed Web of Science ®Google Scholar
• IKEDA M, ISHIDA O, HINOI T, KISHIDA S, KIKUCHI A: Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral. J. Biol. Chem. (1998) 273(2):814-821.
   PubMed Web of Science ®Google Scholar
• ROSSE C, L'HOSTE S, OFFNER N, PICARD A, CAMONIS J: RLIP, an effector of the Ral GTPases, is a platform for Cdk1 to phosphorylate epsin during the switch off of endocytosis in mitosis. J. Biol. Chem. (2003) 278(33):30597-30604.
   PubMed Web of Science ®Google Scholar
• BATTISTA P, PIZZICANNELLA G, VITULLO P, PALMIROTTA R, MARIANI-COSTANTINI R: The epidermal growth factor family in pulmonary carcinoids: immunohistochemical evidence of growth-promoting circuits. Mod. Pathol. (1993) 6(2):162-166.
   PubMed Web of Science ®Google Scholar
• ZHAO J, KIM JE, REED E, LI QQ: Molecular mechanism of antitumor activity of taxanes in lung cancer (review). Int. J. Oncol. (2005) 27(1):247-256.
   PubMed Web of Science ®Google Scholar
• NICAMHLAOIBH R, HEENAN M, CLEARY I et al.: Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. Int. J. Cancer (1999) 82(3):368-376.
   PubMed Web of Science ®Google Scholar
• IKEGAKI N, KATSUMATA M, MINNA J, TSUJIMOTO Y: Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res. (1994) 54(1):6-8.
   PubMed Web of Science ®Google Scholar
• SARTORIUS UA, KRAMMER PH: Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int. J. Cancer (2002) 97(5):584-592.
   PubMed Web of Science ®Google Scholar
• REEVE JG, XIONG J, MORGAN J, BLEEHEN NM: Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br. J. Cancer (1996) 73(10):1193-1200.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, FUJITA N, TSURUO T: p21Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. Int. J. Cancer (1999) 83(6):790-797.
   PubMed Web of Science ®Google Scholar
• PREWITT TW, MATTHEWS W, CHAUDHRI G, POGREBNIAK HW, PASS HI: Tumor necrosis factor induces doxorubicin resistance to lung cancer cells in vitro. J. Thorac. Cardiovasc. Surg. (1994) 107(1):43-49.
   PubMed Web of Science ®Google Scholar
• KIM JY, LEE S, HWANGBO B et al.: NF-κB activation is related to the resistance of lung cancer cells to TNF-α-induced apoptosis. Biochem. Biophys. Res. Commun. (2000) 273(1):140-146.
   PubMed Web of Science ®Google Scholar
• CHENG Q, LEE HH, LI Y, PARKS TP, CHENG G: Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene (2000) 19(42):4936-4940.
   PubMed Web of Science ®Google Scholar
• ANDRIOLLO M, FAVIER A, GUIRAUD P: Adriamycin activates NF-κB in human lung carcinoma cells by IκBα degradation. Arch. Biochem. Biophys. (2003) 413(1):75-82.
   PubMed Web of Science ®Google Scholar
• CHENG JZ, SHARMA R, YANG Y et al.: Accelerated metabolism and exclusion of 4-hydroxynonenal through induction of RLIP76 and hGST5.8 is an early adaptive response of cells to heat and oxidative stress. J. Biol. Chem. (2001) 276(44):41213-41223.
   PubMed Web of Science ®Google Scholar
• SINGHAL SS, AWASTHI YC, AWASTHI S: Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res. (2006) 66(4):2354-2360.
   PubMed Web of Science ®Google Scholar
• SKACEL N, MENON LG, MISHRA PJ et al.: Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate treatment. J. Biol. Chem. (2005) 280(24):22721-22731.
   PubMed Web of Science ®Google Scholar
• TESEI A, RICOTTI L, DE PAOLA F, AMADORI D, FRASSINETI GL, ZOLI W: In vitro schedule-dependent interactions between the multitargeted antifolate LY-231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin. Cancer Res. (2002) 8(1):233-239.
   PubMed Web of Science ®Google Scholar
• SUZUKI T, NISHIO K, TANABE S: The MRP family and anticancer drug metabolism. Curr. Drug Metab. (2001) 2(4):367-377.
   PubMed Web of Science ®Google Scholar
• BINASCHI M, ZUNINO F, CAPRANICO G: Mechanism of action of DNA topoisomerase inhibitors. Stem Cells (1995) 13(4):369-379.
   PubMed Web of Science ®Google Scholar
• BECK WT, DANKS MK: Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin. Cancer Biol. (1991) 2(4):235-244.
   PubMedGoogle Scholar
• WANG JC: Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. (2002) 3(6):430-440.
   PubMed Web of Science ®Google Scholar
• GIACCONE G, GAZDAR AF, BECK H, ZUNINO F, CAPRANICO G: Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res. (1992) 52(7):1666-1674.
   PubMed Web of Science ®Google Scholar
• KANZAWA F, SUGIMOTO Y, MINATO K et al.: Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. (1990) 50(18):5919-5924.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO Y, TSUKAHARA S, OH-HARA T, LIU LF, TSURUO T: Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res. (1990) 50(24):7962-7965.
   PubMed Web of Science ®Google Scholar
• CAPRANICO G, SUPINO R, BINASCHI M et al.: Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol. Pharmacol. (1994) 45(5):908-915.
   PubMed Web of Science ®Google Scholar
• FELDHOFF PW, MIRSKI SE, COLE SP, SULLIVAN DM: Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res. (1994) 54(3):756-762.
   PubMed Web of Science ®Google Scholar
• DINGEMANS AM, WITLOX MA, STALLAERT RA, VAN DER VALK P, POSTMUS PE, GIACCONE G: Expression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin.Cancer Res. (1999) 5(8):2048-2058.
   PubMed Web of Science ®Google Scholar
• LONG BH, WANG L, LORICO A, WANG RC, BRATTAIN MG, CASAZZA AM: Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res. (1991) 51(19):5275-5283.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI K, ISOBE H, HANADA T et al.: Topoisomerase IIα content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Cancer Chemother. Pharmacol. (1997) 39(3):192-198.
   PubMed Web of Science ®Google Scholar
• ZOCHBAUER-MULLER S, GAZDAR AF, MINNA JD: Molecular pathogenesis of lung cancer. Annu. Rev. Physiol. (2002) 64:681-708.
   PubMed Web of Science ®Google Scholar
• ZOCHBAUER-MULLER S, MINNA JD, GAZDAR AF: Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist (2002) 7(5):451-457.
   PubMed Web of Science ®Google Scholar
• VINEIS P, CAPORASO N: Tobacco and cancer: epidemiology and the laboratory. Environ. Health Perspect. (1995) 103(2):156-160.
   PubMed Web of Science ®Google Scholar
• TSAI CM, CHANG KT, LI L, PERNG RP, YANG LY: Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn. J. Cancer Res. (2000) 91(2):213-222.
   PubMedGoogle Scholar
• PETERS GJ, VAN MOORSEL CJ, LAKERVELD B, SMID K et al.: Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Int. J. Oncol. (2006) 28(1):237-244.
   PubMed Web of Science ®Google Scholar
• RAY SD, PATEL D, WONG V, BAGCHI D: In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH-636 grape seed proanthocyanidin extract. Res. Commun. Mol. Pathol. Pharmacol. (2000) 107(1-2):137-166.
   PubMed Web of Science ®Google Scholar
• ZIENOLDDINY S, CAMPA D, LIND H et al.: Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis (2006) 27(3):560-567.
   PubMed Web of Science ®Google Scholar
• GANDHI V, HUANG P, PLUNKETT W: Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk. Lymphoma (1994) 14(Suppl 2):3-9.
   PubMed Web of Science ®Google Scholar
• FRIEDBERG EC: Relationships between DNA repair and transcription. Annu. Rev. Biochem. (1996) 65:15-42.
   PubMed Web of Science ®Google Scholar
• LAGE H, DIETEL M: Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J. Cancer Res. Clin. Oncol. (1999) 125(3-4):156-165.
   PubMed Web of Science ®Google Scholar
• XUE Y, NICHOLSON WL: The two major spore DNA repair pathways, nucleotide excision repair and spore photoproduct lyase, are sufficient for the resistance of Bacillus subtilis spores to artificial UV-C and UV-B but not to solar radiation. Appl. Environ. Microbiol. (1996) 62(7):2221-2227.
   PubMed Web of Science ®Google Scholar
• HILL BT, BELLAMY AS, METCALFE S, HEPBURN PJ, MASTERS JR, WHELAN RD: Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro. Invest. New Drugs (1984) 2(1):29-33.
   PubMed Web of Science ®Google Scholar
• BRUNO T, LEONETTI C, ALOE S et al.: Levels of expression of hRPB11, a core subassembly subunit of human RNA polymerase II, affect doxorubicin sensitivity and cellular differentiation. FEBS Lett. (1998) 427(2):241-246.
   PubMed Web of Science ®Google Scholar
• MODRICH P: Strand-specific mismatch repair in mammalian cells. J. Biol. Chem. (1997) 272(40):24727-24730.
   PubMed Web of Science ®Google Scholar
• JIRICNY J, NYSTROM-LAHTI M: Mismatch repair defects in cancer. Curr. Opin. Genet. Dev. (2000) 10(2):157-161.
   PubMed Web of Science ®Google Scholar
• KARRAN P: Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis (2001) 22(12):1931-1937.
   PubMed Web of Science ®Google Scholar
• FINK D, AEBI S, HOWELL SB: The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. (1998) 4(1):1-6.
   PubMed Web of Science ®Google Scholar
• KAINA B, OCHS K, GROSCH S et al.: BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis. Prog. Nucleic Acid Res. Mol. Biol. (2001) 68:41-54.
   PubMed Web of Science ®Google Scholar
• EGYHAZI S, BERGH J, HANSSON J, KARRAN P, RINGBORG U: Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur. J. Cancer (1991) 27(12):1658-1662.
   PubMed Web of Science ®Google Scholar
• MATTERN J, EICHHORN U, KAINA B, VOLM M: O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int. J. Cancer (1998) 77(6):919-922.
   PubMed Web of Science ®Google Scholar
• OBERLI-SCHRAMMLI AE, JONCOURT F, STADLER M et al.: Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer. Int. J. Cancer (1994) 59(5):629-636.
   PubMed Web of Science ®Google Scholar
• NITURE SK, DONEANU CE, VELU CS, BAILEY NI, SRIVENUGOPAL KS: Proteomic analysis of human O6-methylguanine-DNA methyltransferase by affinity chromatography and tandem mass spectrometry. Biochem. Biophys. Res. Commun. (2005) 337(4):1176-1184.
   PubMed Web of Science ®Google Scholar
• BOULTON SJ, JACKSON SP: Saccharomyces cerevisiae Ku70 potentiates illegitimate DNA double-strand break repair and serves as a barrier to error-prone DNA repair pathways. EMBO J. (1996) 15(18):5093-5103.
   PubMed Web of Science ®Google Scholar
• AYORA S, PIRUAT JI, LUNA R et al.: Characterization of two highly similar Rad51 homologs of Physcomitrella patens. J. Mol. Biol. (2002) 316(1):35-49.
   PubMed Web of Science ®Google Scholar
• OMORI S, TAKIGUCHI Y, SUDA A et al. Suppression of a DNA double-strand break repair gene, Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell line. DNA Repair (2002) 1(4):299-310.
   PubMed Web of Science ®Google Scholar
• CHEAH PL, LOOI LM: p53: an overview of over two decades of study. Malays. J. Pathol. (2001) 23(1):9-16.
   PubMedGoogle Scholar
• SUN Y: p53 and its downstream proteins as molecular targets of cancer. Mol. Carcinog. (2006) 45(6):409-415.
   PubMed Web of Science ®Google Scholar
• AVIS IM, JETT M, BOYLE T et al.: Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J. Clin. Invest. (1996) 97(3):806-813.
   PubMed Web of Science ®Google Scholar
• ADAMS GP, WEINER LM: Monoclonal antibody therapy of cancer. Nat. Biotechnol. (2005) 23(9):1147-1157.
   PubMed Web of Science ®Google Scholar
• ROSS JS, SCHENKEIN DP, PIETRUSKO R et al.: Targeted therapies for cancer 2004. Am. J. Clin. Pathol. (2004) 122(4):598-609.
   PubMed Web of Science ®Google Scholar
• TSAI CM, CHANG KT, WU LH et al.: Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res. (1996) 56(1):206-209.
   PubMed Web of Science ®Google Scholar
• TSAI CM, LEVITZKI A, WU LH et al.: Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. (1996) 56(5):1068-1074.
   PubMed Web of Science ®Google Scholar
• TSAI CM, CHANG KT, LI L, PERNG RP, YANG LY: Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn. J. Cancer Res. (2000) 91(2):213-222.
   PubMedGoogle Scholar
• VOLM M, KOOMAGI R, MATTERN J: Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res. (1996) 16(1):213-217.
   PubMed Web of Science ®Google Scholar
• VOLM M, MATTERN J, KOOMAGI R: Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors. Int. J. Oncol. (1998) 13(5):975-979.
   PubMed Web of Science ®Google Scholar
• ALBERTS DS, GARCIA DJ: Salvage chemotherapy in recurrent or refractory squamous cell cancer of the uterine cervix. Semin. Oncol. (1994) 21(4 Suppl. 7):37-46.
   PubMed Web of Science ®Google Scholar
• FUKUOKA K, SAIJO N: Antimitotic agents. Gan To Kagaku Ryoho (1997) 24(11):1519-1525.
   PubMedGoogle Scholar
• VAN ARK-OTTE J, SAMELIS G, RUBIO G, LOPEZ SAEZ JB, PINEDO HM, GIACCONE G: Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol. Rep. (1998) 5(1):249-255.
   PubMed Web of Science ®Google Scholar
• ACHIWA H, SATO S, SHIMIZU S et al.: Analysis of β-tubulin gene alteration in human lung cancer cell lines. Cancer Lett. (2003) 201(2):211-216.
   PubMed Web of Science ®Google Scholar
• OHTA S, NISHIO K, KUBOTA N et al.: Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn. J. Cancer Res. (1994) 85(3):290-297.
   PubMedGoogle Scholar
• KYU-HO HAN E, GEHRKE L, TAHIR SK et al.: Modulation of drug resistance by α-tubulin in paclitaxel-resistant human lung cancer cell lines. Eur. J. Cancer (2000) 36(12):1565-1571.
   PubMed Web of Science ®Google Scholar
• GONCALVES A, BRAGUER D, KAMATH K et al.: Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc. Natl. Acad. Sci. USA (2001) 98(20):11737-11742.
   PubMed Web of Science ®Google Scholar
• OHTA S, NISHIO K, KUBO S et al.: Characterisation of a vindesine-resistant human small-cell lung cancer cell line. Br. J. Cancer (1993) 68(1):74-79.
   PubMed Web of Science ®Google Scholar
• COLE SP, PINKOSKI MJ, BHARDWAJ G, DEELEY RG: Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br. J. Cancer (1992) 65(4):498-502.
   PubMed Web of Science ®Google Scholar
• HAN EK, TAHIR SK, CHERIAN SP, COLLINS N, NG SC: Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br. J. Cancer (2000) 83(1):83-88.
   PubMed Web of Science ®Google Scholar
• SETHI T, RINTOUL RC, MOORE SM et al.: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. (1999) 5(6):662-668.
   PubMed Web of Science ®Google Scholar
• OSHITA F, KAMEDA Y, IKEHARA M et al.: Increased expression of integrin β1 is a poor prognostic factor in small-cell lung cancer. Anticancer Res. (2002) 22(2B):1065-1070.
   PubMed Web of Science ®Google Scholar
• FRIDMAN R, GIACCONE G, KANEMOTO T, MARTIN GR, GAZDAR AF, MULSHINE JL: Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA (1990) 87(17):6698-6702.
   PubMed Web of Science ®Google Scholar
• BELANGER MM, ROUSSEL E, COUET J: Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs (2003) 14(4):281-287.
   PubMed Web of Science ®Google Scholar
• TROOST J, LINDENMAIER H, HAEFELI WE, WEISS J: Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol. Pharmacol. (2004) 66(5):1332-1339.
   PubMed Web of Science ®Google Scholar
• LI JY, VOLKNANDT W, DAHLSTROM A et al.: Axonal transport of ribonucleoprotein particles (vaults). Neuroscience (1999) 91(3):1055-1065.
   PubMed Web of Science ®Google Scholar
• SHIMAMOTO Y, SUMIZAWA T, HARAGUCHI M et al.: Direct activation of the human major vault protein gene by DNA-damaging agents. Oncol. Rep. (2006) 15(3):645-652.
   PubMed Web of Science ®Google Scholar
• LAURENCOT CM, SCHEFFER GL, SCHEPER RJ, SHOEMAKER RH: Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int. J. Cancer (1997) 72(6):1021-1026.
   PubMed Web of Science ®Google Scholar
• VOLM M, MATTERN J, KOOMAGI R: Expression of lung resistance-related protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance. Anticancer Drugs (1997) 8(10):931-936.
   PubMed Web of Science ®Google Scholar
• KICKHOEFER VA, RAJAVEL KS, SCHEFFER GL, DALTON WS, SCHEPER RJ, ROME LH: Vaults are up-regulated in multidrug-resistant cancer cell lines. J. Biol. Chem. (1998) 273(15):8971-8974.
   PubMed Web of Science ®Google Scholar
• HUFFMAN KE, COREY DR: Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell line. Biochemistry (2005) 44(7):2253-2261.
   PubMed Web of Science ®Google Scholar
• VOLM M, POMMERENKE EW: Associated expression of protein kinase C with resistance to doxorubicin in human lung cancer. Anticancer Res. (1995) 15(2):463-466.
   PubMed Web of Science ®Google Scholar
• DING L, WANG H, LANG W, XIAO L: Protein kinase C-ε promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway. J. Biol. Chem. (2002) 277(38):35305-35313.
   PubMed Web of Science ®Google Scholar
• CLARK AS, WEST KA, BLUMBERG PM, DENNIS PA: Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCδ promotes cellular survival and chemotherapeutic resistance. Cancer Res. (2003) 63(4):780-786.
   PubMed Web of Science ®Google Scholar
• NISHIO K, SUGIMOTO Y, KASAHARA K et al.: Increased phosphorylation of nuclear phosphoproteins in human lung-cancer cells resistant to cis-diamminedichloroplatinum (II). Int. J. Cancer (1992) 50(3):438-442.
   PubMed Web of Science ®Google Scholar
• BROGNARD J, DENNIS PA: Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ. (2002) 9(9):893-904.
   PubMed Web of Science ®Google Scholar
• JOSEPH MG, BANERJEE D, KOCHA W, FELD R, STITT LW, CHERIAN MG: Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome. Cancer (2001) 92(4):836-842.
   PubMed Web of Science ®Google Scholar
• RICHARDS EH, HICKEY E, WEBER L, MASTER JR: Effect of overexpression of the small heat shock protein HSP-27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res. (1996) 56(10):2446-2451.
   PubMed Web of Science ®Google Scholar
• HU Y, MIVECHI NF: HSF-1 interacts with Ral-binding protein 1 in a stress-responsive, multiprotein complex with HSP90 in vivo. J. Biol. Chem. (2003) 278(19):17299-17306.
   PubMed Web of Science ®Google Scholar
• SINGHAL SS, AWASTHI S: Glutathione-conjugate transport and stress-response signaling: role of RLIP76. In: Toxicology of Glutathione S-Transferases. Awasthi YC (Ed.), CRC Press, Boca Raton, FL, USA (2006):231-256.
   Google Scholar
• FUJIWARA Y, SUGIMOTO Y, KASAHARA K et al.: Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn. J. Cancer Res. (1990) 81(5):527-535.
   PubMedGoogle Scholar
• MEIJER C, MULDER NH, HOSPERS GA, UGES DR, DE VRIES EG: The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br. J. Cancer (1990) 62(1):72-77.
   PubMed Web of Science ®Google Scholar
• MEIJER C, MULDER NH, TIMMER-BOSSCHA H, SLUITER WJ, MEERSMA GJ, DE VRIES EG: Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. (1992) 52(24):6885-6889.
   PubMed Web of Science ®Google Scholar
• KUROKAWA H, ISHIDA T, NISHIO K et al.: γ-Glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem. Biophys. Res. Commun. (1995) 216(1):258-264.
   PubMed Web of Science ®Google Scholar
• HAO XY, BERGH J, BRODIN O, HELLMAN U, MANNERVIK B: Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis (1994) 15(6):1167-1173.
   PubMed Web of Science ®Google Scholar
• HIDA T, ARIYOSHI Y, KUWABARA M et al.: Glutathione S-transferase π levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity. Jpn. J. Clin. Oncol. (1993) 23:14-19.
   PubMed Web of Science ®Google Scholar
• AWASTHI S, SHARMA R, SINGHAL SS, HERZOG NK, CHAUBEY M, AWASTHI YC: Modulation of cisplatin cytotoxicity by sulphasalazine. Br. J. Cancer (1994) 70(2):190-194.
   PubMed Web of Science ®Google Scholar
• ISHII T, TERAMOTO S, MATSUSE T: GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells. Cancer Lett. (2004) 216(1):89-102.
   PubMed Web of Science ®Google Scholar
• BAI F, NAKANISHI Y, KAWASAKI M et al.: Immunohistochemical expression of glutathione S-transferase-π can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer (1996) 78(3):416-421.
   PubMed Web of Science ®Google Scholar
• BERHANE K, HAO XY, EGYHAZI S, HANSSON J, RINGBORG U, MANNERVIK B: Contribution of glutathione transferase M3-3 to 1,3-bis(2-chloroethyl)-1-nitrosourea resistance in a human non-small cell lung cancer cell line. Cancer Res. (1993) 53(18):4257-4261.
   PubMed Web of Science ®Google Scholar
• WAREING CJ, BLACK SM, HAYES JD, WOLF CR: Increased levels of α-class and π-class glutathione S-transferases in cell lines resistant to 1-chloro-2,4-dinitrobenzene. Eur. J. Biochem. (1993) 217(2):671-676.
   PubMedGoogle Scholar
• SHARMA R, SINGHAL SS, SRIVASTAVA SK, BAJPAI KK, FRENKEL EP, AWASTHI S: Glutathione and glutathione linked enzymes in human small cell lung cancer cell lines. Cancer Lett. (1993) 75(2):111-119.
   PubMed Web of Science ®Google Scholar
• INOUE T, ISHIDA T, SUGIO K, MAEHARA Y, SUGIMACHI K: Glutathione S transferase π is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma. Respiration (1995) 62(4):223-227.
   PubMed Web of Science ®Google Scholar
• VOLM M, KOOMAGI R, MATTERN J, STAMMLER G: Heat shock (hsp70) and resistance proteins in non-small cell lung carcinomas. Cancer Lett. (1995) 95(1-2):195-200.
   PubMed Web of Science ®Google Scholar
• BORST P, EVERS R, KOOL M, WIJNHOLDS J: The multidrug resistance protein family. Biochim. Biophys. Acta (1999) 1461(2):347-357.
   PubMed Web of Science ®Google Scholar
• COLE SP, BHARDWAJ G, GERLACH JH et al.: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (1992) 258(5088):1650-1654.
   PubMed Web of Science ®Google Scholar
• SARKADI B, OZVEGY-LACZKA C, NEMET K, VARADI A: ABCG2 – a transporter for all seasons. FEBS Lett. (2004) 567(1):116-120.
   PubMed Web of Science ®Google Scholar
• SCHISSELBAUER JC, CRESCIMANNO M, D'ALESSANDRO N et al.: Glutathione, glutathione S-transferases, and related redox enzymes in Adriamycin-resistant cell lines with a multidrug resistant phenotype. Cancer Commun. (1989) 1(2):133-139.
   PubMedGoogle Scholar
• SHARMA R, ARNOLD L, GULLIYA KS: Correlation between DNA topoisomerase II activity and cytotoxicity in pMC540 and merodantoin sensitive and resistant human breast cancer cells. Anticancer Res. (1995) 15(2):295-304.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, FUJIWARA Y, YAMAKIDO M, KATOH O, WATANABE H, MACKENZIE PI: The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. Jpn. J. Cancer Res. (1997) 88(12):1211-1217.
   PubMedGoogle Scholar
• KOJIMA A, HACKETT NR, CRYSTAL RG: Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA. Cancer Res. (1998) 58(19):4368-4374.
   PubMed Web of Science ®Google Scholar
• SINGH SV, SCALAMOGNA D, XIA H et al.: Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line. Int. J. Cancer (1996) 65(6):852-857.
   PubMed Web of Science ®Google Scholar
• BANDO T, KASAHARA K, SHIBATA K et al.: Role of sodium pump systems to determine sensitivity to mitomycin C in non-small cell lung cancer cell lines. Anticancer Res. (1995) 15(3):769-772.
   PubMed Web of Science ®Google Scholar
• SHIBATA K, KASAHARA K, BANDO T et al.: Establishment and characterization of non-small cell lung cancer cell lines resistant to mitomycin C under aerobic conditions. Jpn. J. Cancer Res. (1995) 86(5):460-469.
   PubMedGoogle Scholar
• GRAZIANI G, FARAONI I, GROHMANN U et al.: O6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia. Cancer Res. (1995) 55(24):6231-6236.
   PubMed Web of Science ®Google Scholar
• UENISHI R, GONG P, SUZUKI K, KOIZUMI S: Cross talk of heat shock and heavy metal regulatory pathways. Biochem. Biophys. Res. Commun. (2006) 341(4):1072-1077.
   PubMed Web of Science ®Google Scholar
• TWENTYMAN PR, WRIGHT KA, RHODES T: Radiation response of human lung cancer cells with inherent and acquired resistance to cisplatin. Int. J. Radiat. Oncol. Biol. Phys. (1991) 20:217-220.
   PubMed Web of Science ®Google Scholar
• LOCKE VL, DAVEY RA, DAVEY MW: Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel. Anticancer Drugs (2003) 14(7):523-531.
   PubMed Web of Science ®Google Scholar
• REED E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. (1998) 24(5):331-344.
   PubMed Web of Science ®Google Scholar
• MOLLENHAUER HH, MORRE DJ, ROWE LD: Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity. Biochim. Biophys. Acta (1990) 1031(2):225-246.
   PubMed Web of Science ®Google Scholar
• SUZUKI T, NISHIO K, TANABE S: The MRP family and anticancer drug metabolism. Curr. Drug Metab. (2001) 2(4):367-377.
   PubMed Web of Science ®Google Scholar
• GORLICK R, COLE P, BANERJEE D et al.: Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation. Adv. Exp. Med. Biol. (1999) 457:543-550.
   PubMed Web of Science ®Google Scholar
• WEBER G, NAGAI M, NATSUMEDA Y et al.: Regulation of de novo and salvage pathways in chemotherapy. Adv. Enzyme Regul. (1991) 31:45-67.
   PubMedGoogle Scholar
• BANERJEE D, MAYER-KUCKUK P, CAPIAUX G, BUDAK-ALPDOGAN T, GORLICK R, BERTINO JR: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim. Biophys. Acta (2002) 1587(2-3):164-173.
   PubMed Web of Science ®Google Scholar
• SIERRA EE, GOLDMAN ID: Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin. Oncol. (1999) 26(2 Suppl 6):11-23.
   PubMedGoogle Scholar
• CHEN ZS, GUO Y, BELINSKY MG, KOTOVA E, KRUH GD: Transport of bile acids, sulfated steroids, estradiol 17-β-d-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol. Pharmacol. (2005) 67(2):545-557.
   PubMed Web of Science ®Google Scholar
• BAI J, LAI L, YEO HC, GOH BC, TAN TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int. J. Biochem. Cell Biol. (2004) 36(2):247-257.
   PubMed Web of Science ®Google Scholar
• ELKIND NB, SZENTPETERY Z, APATI A et al.: Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor iressa (ZD-1839, gefitinib). Cancer Res. (2005) 65(5):1770-1777.
   PubMed Web of Science ®Google Scholar
• BIEDLER JL, SPENGLER BA: Reverse transformation of multidrug-resistant cells. Cancer Metastasis Rev. (1994) 13(2):191-207.
   PubMed Web of Science ®Google Scholar
• VOLM M, KOOMAGI R, MATTERN J, EFFERTH T: Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br. J. Cancer (2002) 87(3):251-257.
   PubMed Web of Science ®Google Scholar
• VOLM M, EFFERTH T, MATTERN J: Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res. (1992) 12(1):11-20.
   PubMed Web of Science ®Google Scholar
• OKA M, FUKUDA M, SAKAMOTO A et al.: The clinical role of MDR1 gene expression in human lung cancer. Anticancer Res. (1997) 17(1B):721-724.
   PubMed Web of Science ®Google Scholar
• KASAHARA K, FUJIWARA Y, SUGIMOTO Y et al.: Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J. Natl. Cancer Inst. (1992) 84(2):113-118.
   PubMed Web of Science ®Google Scholar
• GIACCONE G, VAN ARK-OTTE J, RUBIO GJ et al.: MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int. J. Cancer (1996) 66(6):760-767.
   PubMed Web of Science ®Google Scholar
• YOUNG LC, CAMPLING BG, COLE SP, DEELEY RG, GERLACH JH: Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin.Cancer Res. (2001) 7(6):1798-1804.
   PubMed Web of Science ®Google Scholar
• CARMICHAEL J, MITCHELL JB, FRIEDMAN N, GAZDAR AF, RUSSO A: Glutathione and related enzyme activity in human lung cancer cell lines. Br. J. Cancer (1988) 58(4):437-440.
   PubMed Web of Science ®Google Scholar
• SINGHAL SS, YADAV S, SINGHAL J, DRAKE K, AWASTHI YC, AWASTHI S: The role of PKCα and RLIP76 in transport-mediated doxorubicin-resistance in lung cancer. FEBS Lett. (2005) 579(21):4635-4641.
   PubMed Web of Science ®Google Scholar
• SINGHAL SS, WICKRAMARACHCHI D, SINGHAL J, YADAV S, AWASTHI YC, AWASTHI S: Determinants of differential doxorubicin sensitivity between SCLC and NSCLC. FEBS Lett. (2006) 580(9):2258-2264.
   PubMed Web of Science ®Google Scholar
• SHARMA R, SINGHAL SS, WICKRAMARACHCHI D, AWASTHI YC, AWASTHI S: RLIP76 (RALBP1)-mediated transport of leukotriene C4 (LTC4) in cancer cells: implications in drug resistance. Int. J. Cancer (2004) 112(6):934-942.
   PubMed Web of Science ®Google Scholar
• PARK SH, WEINBERG RA: A putative effector of Ral has homology to Rho/Rac GTPase activating proteins. Oncogene (1995) 11:2349-2355.
   PubMed Web of Science ®Google Scholar
• CANTOR SB, URANO T, FEIG LA: Identification and characterization of Ral-binding protein 1, a potential downstream target of Ral GTPases. Mol. Cell Biol. (1995) 15:4578-4584.
   PubMed Web of Science ®Google Scholar
• JULLIEN-FLORES V, DORSEUIL O, ROMERO F et al.: Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity. J. Biol. Chem. (1995) 270:22473-22477.
   PubMed Web of Science ®Google Scholar
• AWASTHI S, SINGHAL SS, SRIVASTAVA SK et al.: Adenosine triphosphate-dependent transport of doxorubicin, daunomyicn, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. J. Clin. Invest. (1994) 93:958-965.
   PubMed Web of Science ®Google Scholar
• AWASTHI S, SINGHAL SS, SRIVASTAVA SK et al.: ATP-Dependent human erythrocyte glutathione-conjugate transporter. I. Purification, photoaffinity labeling, and kinetic characteristics of ATPase activity. Biochemistry (1998) 37:5231-5238.
   PubMed Web of Science ®Google Scholar
• AWASTHI S, SINGHAL SS, PIKULA S et al.: ATP-dependent human erythrocyte glutathione-conjugate transporter. II. Functional reconstitution of transport activity. Biochemistry (1998) 37:5239-5248.
   Google Scholar
• LABELLE EF, SINGH SV, SRIVASTAVA SK, AWASTHI YC: Dinitrophenyl glutathione efflux from human erythrocytes is primary active ATP-dependent transport. Biochem. J. (1986) 238(2):443-449.
   PubMed Web of Science ®Google Scholar
• SHARMA R, GUPTA S, SINGH SV et al.: Purification and characterization of dinitrophenylglutathione ATPase of human erythrocytes and its expression in other tissues. Biochem. Biophys. Res. Commun. (1990) 171:155-161.
   PubMed Web of Science ®Google Scholar
• SINGHAL SS, SHARMA R, GUPTA S et al.: The anionic conjugates of bilirubin and bile acids stimulate ATP hydrolysis by S-(dinitrophenyl) glutathione ATPase of human erythrocyte. FEBS Lett. (1991) 281:255-257.
   PubMed Web of Science ®Google Scholar
• AWASTHI YC, SINGHAL SS, GUPTA S et al.: Purification and characterization of an ATPase from human liver which catalyzes ATP hydrolysis in presence of the conjugates of bilirubin, bile acids and glutathione. Biochem. Biophys. Res. Commun. (1991) 175:1090-1096.
   PubMed Web of Science ®Google Scholar
• SAXENA M, SINGHAL SS, AWASTHI S et al.: Dinitrophenyl S-glutathione ATPase purified from human muscle catalyzes ATP hydrolysis in the presence of leukotrienes. Arch. Biochem. Biophys. (1992) 298(1):231-237.
   PubMed Web of Science ®Google Scholar
• AWASTHI S, CHENG J, SINGHAL SS et al.: Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin. Biochemistry (2000) 39(31):9327-9334.
   PubMed Web of Science ®Google Scholar
• AWASTHI S, CHENG JZ, SINGHAL SS et al.: Functional reassembly of ATP-dependent xenobiotic transport by the N- and C-terminal domains of RLIP76 and identification of ATP binding sequences. Biochemistry (2001) 40(13):4159-4168.
   PubMed Web of Science ®Google Scholar
• SHARMA R, AWASTHI YC, YANG Y et al.: Energy-dependent transport of xenobiotics and its relevance to multidrug resistance. Curr. Cancer Drug Targets (2003) 3:89-107.
   PubMed Web of Science ®Google Scholar
• YANG Y, SHARMA A, SHARMA R et al.: Cells preconditioned with mild, transient UVA irradiation acquire resistance to oxidative stress and UVA-induced apoptosis: role of 4-hydroxynonenal in UVA-mediated signaling for apoptosis. J. Biol. Chem. (2003) 278(42):41380-41388.
   PubMed Web of Science ®Google Scholar
• SHARMA R, SINGHAL SS, CHENG J et al.: RLIP76 is the major ATP-dependent transporter of glutathione-conjugates and doxorubicin in human erythrocytes. Arch. Biochem. Biophys. (2001) 391(2):171-179.
   PubMed Web of Science ®Google Scholar
• YADAV S, SINGHAL SS, SINGHAL J et al.: Identification of membrane-anchoring domains of RLIP76 using deletion mutant analyses. Biochemistry (2004) 43(51):16243-16253.
   PubMed Web of Science ®Google Scholar
• YADAV S, ZAJAC E, SINGHAL SS et al.: POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates, drugs and promotes apoptosis. Biochem. Biophys. Res. Commun. (2005) 328(4):1003-1009.
   PubMed Web of Science ®Google Scholar
• SINGHAL SS, YADAV S, SINGHAL J, ZAJAC E, AWASTHI YC, AWASTHI S: Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Biochem. Pharmacol. (2005) 70(3):481-488.
   PubMed Web of Science ®Google Scholar
• MATSUZAKI T, HANAI S, KISHI H et al.: Regulation of endocytosis of activin type II receptors by a novel PDZ protein through Ral/Ral-binding protein 1-dependent pathway. J. Biol. Chem. (2002) 277(21):19008-19018.
   PubMed Web of Science ®Google Scholar
• OOSTERHOFF JK, KUHNE LC, GROOTEGOED JA, BLOK LJ: EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2. Int. J. Cancer (2005) 113(4):561-567.
   PubMed Web of Science ®Google Scholar
• JULLIEN-FLORES V, MAHE Y, MIREY GH et al.: RLIP76, an effector of the GTPase Ral, interacts with AP2 complex: involvement of the Ral pathway in receptor endocytosis. J. Cell Sci. (2000) 113:2837-2844.
   PubMed Web of Science ®Google Scholar
• MIREY G, BALAKIREVA M, L'HOSTE S, ROSSE C, VOEGELING S, CAMONIS J: A Ral guanine exchange factor-Ral pathway is conserved in Drosophila melanogaster and sheds new light on the connectivity of the Ral, Ras, and Rap pathways. Mol. Cell. Biol. (2003) 23(3):1112-1124.
   PubMed Web of Science ®Google Scholar
• BAUER B, MIREY G, VETTER IR et al.: Effector recognition by the small GTP-binding proteins Ras and Ral. J. Biol. Chem. (1999) 274(25):17763-17770.
   PubMed Web of Science ®Google Scholar
• CULLIS DN, PHILIP B, BALEJA JD, FEIG LA: Rab11-FIP2, an adaptor protein connecting cellular components involved in internalization and recycling of epidermal growth factor receptors. J. Biol. Chem. (2002) 277(51):49158-49166.
   PubMed Web of Science ®Google Scholar
• KARIYA K, KOYAMA S, NAKASHIMA S, OSHIRO T, MORINAKA K, KIKUCHI A: Regulation of complex formation of POB1/epsin/adaptor protein complex 2 by mitotic phosphorylation. J. Biol. Chem. (2000) 275(24):18399-18406.
   PubMed Web of Science ®Google Scholar
• OOSTERHOFF JK, PENNINKHOF F, BRINKMANN AO, ANTON GROOTEGOED J, BLOK LJ: REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells. Oncogene (2003) 22(19):2920-2925.
   PubMed Web of Science ®Google Scholar
• PENNINKHOF F, GROOTEGOED JA, BLOK LJ: Identification of REPS2 as a putative modulator of NF-κB activity in prostate cancer cells. Oncogene (2004) 23(33):5607-5615.
   PubMed Web of Science ®Google Scholar
• ZIMNIAK P, AWASTHI S, AWASTHI YC: Phase III detoxification system. Trends Biochem. Sci. (1993) 18(5):164-166.
   PubMed Web of Science ®Google Scholar
• WIJNHOLDS J, EVERS R, VAN LEUSDEN MR et al.: Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med. (1997) 3(11):1275-1279.
   PubMed Web of Science ®Google Scholar
• LORICO A, RAPPA G, FINCH RA, YANG D, FLAVELL RA, SARTORELLI AC: Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res. (1997) 57(23):5238-5242.
   PubMed Web of Science ®Google Scholar
• AWASTHI S, SRIVASTAVA SK, AHMAD F, AHMAD H, ANSARI GA: Interactions of glutathione S-transferase-π with ethacrynic acid and its glutathione conjugate. Biochim. Biophys. Acta (1993) 1164(2):173-178.
   PubMed Web of Science ®Google Scholar
• SHARMA R, BROWN D, AWASTHI S et al.: Transfection with 4-hydroxynonenal-metabolizing glutathione S-transferase isozymes leads to phenotypic transformation and immortalization of adherent cells. Eur. J. Biochem. (2004) 271(9):1690-1701.
   PubMedGoogle Scholar
• CHENG JZ, SINGHAL SS, SAINI M et al.: Effects of mGST A4 transfection on 4-hydroxynonenal-mediated apoptosis and differentiation of K562 human erythroleukemia cells. Arch. Biochem. Biophys. (1999) 372(1):29-36.
   PubMed Web of Science ®Google Scholar
• CHENG JZ, SINGHAL SS, SHARMA A et al.: Transfection of mGSTA4 in HL-60 cells protects against 4-hydroxynonenal-induced apoptosis by inhibiting JNK-mediated signaling. Arch. Biochem. Biophys. (2001) 392(2):197-207.
   PubMed Web of Science ®Google Scholar
• CAMANDOLA S, POLI G, MATTSON MP: The lipid peroxidation product 4-hydroxy-2,3-nonenal increases AP-1-binding activity through caspase activation in neurons. J. Neurochem. (2000) 74(1):159-168.
   PubMed Web of Science ®Google Scholar
• AWASTHI YC, YANG Y, TIWARI NK et al.: Regulation of 4-hydroxynonenal-mediated signaling by glutathione S-transferases. Free Radic. Biol. Med. (2004) 37(5):607-619.
   PubMed Web of Science ®Google Scholar
• RAMANA KV, BHATNAGAR A, SRIVASTAVA S et al.: Mitogenic responses of vascular smooth cells to lipid peroxidation-derived aldehyde 4-hydroxy-trans-2-nonenal (HNE): role of aldose reductase-catalyzed reduction of the HNE-glutathione conjugates in regulating cell growth. J. Biol. Chem. (2006) 281:17652-17660.
   PubMed Web of Science ®Google Scholar
• LOE DW, ALMQUIST KC, DEELEY RG, COLE SP: Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. (1996) 271:9675-9682.
   PubMed Web of Science ®Google Scholar
• AGAPOVA LS, VOLODINA JL, CHUMAKOV PM, KOPNIN BP: Activation of Ras-Ral pathway attenuates p53-independent DNA damage G2 checkpoint. J. Biol. Chem. (2004) 279(35):36382-36389.
   PubMed Web of Science ®Google Scholar
• GOODFELLOW HR, SARDINI A, RUETZ S et al.: Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J. Biol. Chem. (1996) 271(23):13668-13674.
   PubMed Web of Science ®Google Scholar
• DHANASEKARAN SM, BARRETTE TR, GHOSH D et al.: Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 412(6849):822-826.
   PubMed Web of Science ®Google Scholar
• DING S, GONG BD, YU J et al.: Methylation profile of the promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma. World J. Gastroenterol. (2004) 10(23):3433-3440.
   PubMed Web of Science ®Google Scholar
• BERGER W, SETINEK U, HOLLAUS P et al.: Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J. Cancer Res. Clin. Oncol. (2005) 131(6):355-363.
   PubMed Web of Science ®Google Scholar
• KAWABATA S, OKA M, SHIOZAWA K et al.: Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun. (2001) 280(5):1216-1223.
   PubMed Web of Science ®Google Scholar
• OGURI T, TAKAHASHI T, MIYAZAKI M et al.: UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res. (2004) 24:2893-2896.
   PubMed Web of Science ®Google Scholar
• YEH JJ, HSU NY, HSU WH, TSAI CH, LIN CC, LIANG JA: Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung (2005) 183(3):177-183.
   PubMed Web of Science ®Google Scholar
• TIAN Q, ZHANG J, CHAN SY et al.: Topotecan is a substrate for multidrug resistance associated protein 4. Curr. Drug Metab. (2006) 7(1):105-118.
   PubMed Web of Science ®Google Scholar
• RYBAROVA S, HAJDUKOVA M, HODOROVA I et al.: Expression of the multidrug resistance-associated protein 1 (MRP1) and the lung resistance-related protein (LRP) in human lung cancer. Neoplasma (2004) 51(3):169-174.
   PubMed Web of Science ®Google Scholar
• HOVELMANN S, BECKERS TL, SCHMIDT M: Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells. Br. J. Cancer (2004) 90:2370-2377.
   PubMed Web of Science ®Google Scholar
• MATHIEU A, REMMELINK M, D'HAENE N et al.: Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-α (GST)-α, GST-µ, and GST-π. Cancer (2004) 101(8):1908-1918.
   PubMed Web of Science ®Google Scholar
• TSURUTANI J, WEST KA, SAYYAH J, GILLS JJ, DENNIS PA: Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. (2005) 65(18):8423-8432.
   PubMed Web of Science ®Google Scholar
• HENNESS S, DAVEY MW, HARVIE RM, DAVEY RA: Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIα expression. Int. J. Radiat. Oncol. Biol. Phys. (2002) 54(3):895-902.
   PubMed Web of Science ®Google Scholar
• STAMMLER G, POMMERENKE EW, MATTERN J, VOLM M: Effects of single doses of irradiation on the expression of resistance-related proteins in murine NIH 3T3 and human lung carcinoma cells. Carcinogenesis (1995) 16(9):2051-2055.
   PubMed Web of Science ®Google Scholar
• ELIAS AD: Advances in the diagnosis and management of sarcomas. Curr. Opin. Oncol. (1992) 4(4):681-688.
   PubMedGoogle Scholar
• MULLER JG, BUCHELER US, KAYSER K, SCHIRMER RH, WERNER D, KRAUTH-SIEGEL RL: Glutathione reductase in human and murine lung tumors: high levels of mRNA and enzymatic activity. Cell. Mol. Biol. (Noisy-le-grand) (1993) 39(4):389-396.
   PubMed Web of Science ®Google Scholar
• ROBEY RW, STEADMAN K, POLGAR O, BATES SE: ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer. Biol. Ther. (2005) 4:187-194.
   PubMed Web of Science ®Google Scholar
• MATTERN J, EFFERTH T, VOLM M: Overexpression of P-glycoprotein in human lung carcinoma xenografts after fractionated irradiation in vivo. Radiat. Res. (1991) 127(3):335-338.
   PubMed Web of Science ®Google Scholar
• BROGNARD J, CLARK AS, NI Y, DENNIS PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. (2001) 61(10):3986-3997.
   PubMed Web of Science ®Google Scholar
• BRUNNER TB, HAHN SM, MCKENNA WG, BERNHARD EJ: Radiation sensitization by inhibition of activated Ras. Strahlenther. Onkol. (2004) 180(11):731-740.
   PubMed Web of Science ®Google Scholar
• SANDLER AB, DUBINETT SM: COX-2 inhibition and lung cancer. Semin. Oncol. (2004) 31(2 Suppl 7):45-52.
   PubMed Web of Science ®Google Scholar
• HODKINSON PS, ELLIOTT T, WONG WS et al.: ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase. Cell Death Differ. (2006) (In Press).
   PubMedGoogle Scholar
• DENLINGER CE, RUNDALL BK, JONES DR: Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-κB. Semin. Thorac. Cardiovasc. Surg. (2004) 16(1):28-39.
   PubMedGoogle Scholar
• SHINODA C, MARUYAMA M, FUJISHITA T et al.: Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway. Int. J. Cancer (2005) 117(1):21-31.
   PubMed Web of Science ®Google Scholar
• BELANGER MM, GAUDREAU M, ROUSSEL E, COUET J: Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells. Cancer. Biol. Ther. (2004) 3(10):954-959.
   PubMed Web of Science ®Google Scholar
• JAIN A, TINDELL CA, LAUX I et al.: Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc. Natl. Acad. Sci. USA (2005) 102(33):11858-11863.
   PubMed Web of Science ®Google Scholar
• HARTMANN TN, BURGER JA, GLODEK A, FUJII N, BURGER M: CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene (2005) 24(27):4462-4471.
   PubMed Web of Science ®Google Scholar
• TARON M, ROSELL R, FELIP E et al.: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet. (2004) 13(20):2443-2449.
   PubMed Web of Science ®Google Scholar
• UGOCSAI K, MANDOKY L, TISZLAVICZ L, MOLNAR J: Investigation of HER2 overexpression in non-small cell lung cancer. Anticancer Res. (2005) 25(4):3061-3066.
   PubMed Web of Science ®Google Scholar
• ROSELL R, TARON M, BARNADAS A, SCAGLIOTTI G, SARRIES C, ROIG B: Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control (2003) 10(4):297-305.
   PubMedGoogle Scholar
• ZHOU W, GURUBHAGAVATULA S, LIU G et al.: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. (2004) 10(15):4939-4943.
   PubMed Web of Science ®Google Scholar
• OGURI T, ACHIWA H, BESSHO Y et al.: The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer (2005) 49(3):345-351.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI N, SHIOTANI T, YAMAJI Y, FUJITA J, HATA Y, IRINO S: Establishment and biochemical properties of cis-diamminedichloroplatinum(II)-resistant A549 lung cancer cells. Cancer Biochem. Biophys. (1991) 12(3):177-183.
   PubMedGoogle Scholar
• HANSEN LT, LUNDIN C, SPANG-THOMSEN M, PETERSEN LN, HELLEDAY T: The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int. J. Cancer (2003) 105(4):472-479.
   PubMed Web of Science ®Google Scholar
• ZHANG ZZ, ZHANG Q, WU M: Constructing the eukaryotic expression vector to study preliminarily the functions of hammerhead ribozyme targeting base excision repair gene HOGG1. Sichuan Da Xue Xue Bao Yi Xue Ban (2006) 37(2):165-170.
   PubMedGoogle Scholar
• HANSEN LT, LUNDIN C, HELLEDAY T et al.: DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer. Lung Cancer (2003) 40(2):157-164.
   PubMed Web of Science ®Google Scholar
• KUBO S, MATSUTANI M, NAKAGAWA K, OGURA T, ESUMI H, SAIJO N: Participation of poly(ADP-ribose) polymerase in the drug sensitivity in human lung cancer cell lines. J. Cancer Res. Clin. Oncol. (1992) 118(4):244-248.
   PubMed Web of Science ®Google Scholar
• SONG L, COPPOLA D, LIVINGSTON S, CRESS D, HAURA EB: Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer. Biol. Ther. (2005) 4(3):267-276.
   PubMed Web of Science ®Google Scholar
• VIKTORSSON K, EKEDAHL J, LINDEBRO MC et al.: Defective stress kinase and Bak activation in response to ionizing radiation but not cisplatin in a non-small cell lung carcinoma cell line. Exp.Cell Res. (2003) 289(2):256-264.
   PubMed Web of Science ®Google Scholar
• EKEDAHL J, JOSEPH B, MARCHETTI P et al.: Heat shock protein 72 does not modulate ionizing radiation-induced apoptosis in U1810 non-small cell lung carcinoma cells. Cancer Biol. Ther. (2003) 2(6):663-669.
   PubMed Web of Science ®Google Scholar
• FOKKEMA E, DE VRIES EG, GROEN HJ, MEIJER C, TIMENS W: Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment. Virchows Arch. (2003) 442(4):349-355.
   PubMed Web of Science ®Google Scholar
• ROSELL R, FOSSELLA F, MILAS L; SPANISH LUNG CANCER GROUP: Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer (2002) 38(Suppl 4):43-49.
   PubMed Web of Science ®Google Scholar
• CORDES N, BLAESE MA, PLASSWILM L, RODEMANN HP, VAN BEUNINGEN D: Fibronectin and laminin increase resistance to ionizing radiation and the cytotoxic drug Ukrain in human tumour and normal cells in vitro. Int. J. Radiat. Biol. (2003) 79(9):709-720.
   PubMed Web of Science ®Google Scholar
• HARDING J, BURTNESS B: Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) (2005) 41(2):107-127.
   PubMed Web of Science ®Google Scholar
• NAMBA Y, KIJIMA T, YOKOTA S et al.: Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin. Lung Cancer (2004) 6(2):123-128.
   PubMedGoogle Scholar
• JUNKER K, STACHETZKI U, RADEMACHER D et al.: HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. Lung Cancer (2005) 48(1):59-67.
   PubMed Web of Science ®Google Scholar
• BROOKS KR, TO K, JOSHI MB et al.: Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann. Thorac. Surg. (2003) 76(1):187-193.
   PubMed Web of Science ®Google Scholar
• CALABRESE CR, ALMASSY R, BARTON S et al.: Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. (2004) 96(1):56-67.
   PubMed Web of Science ®Google Scholar